Factors influencing the efficacy of nebulized colistimethate sodium in the treatment of severe lung infection caused by carbapenem-resistant gram-negative bacteria
Abstract
BACKGROUND
Nebulized colistimethate sodium (CMS) can help treat carbapenem-resistant gram-negative bacteria (CR-GNB) infection. However, it remains unclear how various patient-related factors affect its efficacy.
METHODS
This was a secondary analysis of a multicenter retrospective study involving 24 hospitals in China. Patients diagnosed with severe pneumonia caused by CR-GNB and who received nebulized CMS 75 mg every 12 h for at least 3 days were included. Logistic regression was performed to examine associations with clinical outcomes.
RESULTS
A total of 314 patients were included, with an average age of 68.9 years, and 77.4% were male. Most patients (89.2%) had no history of CR-GNB infection. Pathogens exhibited resistance to imipenem (90.4%), meropenem (90.1%), and ampicillin/sulbactam (82.5%). Following treatment, the cohort achieved 76.1% microbiological efficacy and 79.3% overall clinical response rate. The mortality rate was 20.1%. Multivariable analysis revealed that age (adjusted odds ratio [aOR], 0.96; 95% confidence interval [CI], 0.92-0.997, P = 0.04), history of stroke (aOR, 0.16; 95% CI, 0.04-0.77, P = 0.02), and combination treatment with tigecycline (aOR, 0.11; 95% CI, 0.22-0.50; P = 0.004) were independently associated with lower bacterial clearance. Use of moxifloxacin before CMS administration (aOR, 0.11; 95% CI, 0.02-0.55; P = 0.007) and tigecycline treatment (aOR, 0.19; 95% CI, 0.06-0.58; P = 0.003) were associated with a lower clinical response. After…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 314 participants or records.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.